EE04589B1 - Vähivastaste ühendite valmistamise protsessid ja vaheühendid - Google Patents

Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Info

Publication number
EE04589B1
EE04589B1 EEP200000255A EEP200000255A EE04589B1 EE 04589 B1 EE04589 B1 EE 04589B1 EE P200000255 A EEP200000255 A EE P200000255A EE P200000255 A EEP200000255 A EE P200000255A EE 04589 B1 EE04589 B1 EE 04589B1
Authority
EE
Estonia
Prior art keywords
intermediates
processes
preparation
anticancer compounds
anticancer
Prior art date
Application number
EEP200000255A
Other languages
English (en)
Inventor
Shelton Lehner Richard
Norris Timothy
Paul Santafianos Dinos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000255A publication Critical patent/EE200000255A/et
Publication of EE04589B1 publication Critical patent/EE04589B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling
EEP200000255A 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid EE04589B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (2)

Publication Number Publication Date
EE200000255A EE200000255A (et) 2000-12-15
EE04589B1 true EE04589B1 (et) 2006-02-15

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000255A EE04589B1 (et) 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Country Status (50)

Country Link
US (1) US6476040B1 (et)
EP (1) EP1044969B1 (et)
JP (2) JP3420549B2 (et)
KR (2) KR100430210B1 (et)
CN (2) CN1215061C (et)
AP (2) AP1655A (et)
AR (1) AR018705A1 (et)
AT (1) ATE348098T1 (et)
AU (2) AU781402B2 (et)
BG (1) BG65194B1 (et)
BR (1) BRPI0001486B8 (et)
CA (2) CA2302965C (et)
CO (1) CO5160273A1 (et)
CR (1) CR6165A (et)
CZ (1) CZ299426B6 (et)
DE (1) DE60032275T2 (et)
DK (1) DK1044969T3 (et)
DZ (1) DZ3030A1 (et)
EA (3) EA005892B1 (et)
EE (1) EE04589B1 (et)
EG (1) EG22506A (et)
ES (1) ES2278578T3 (et)
GE (1) GEP20022653B (et)
GT (1) GT200000037A (et)
HK (1) HK1029790A1 (et)
HR (1) HRP20000182B1 (et)
HU (1) HU227698B1 (et)
ID (1) ID25427A (et)
IL (2) IL135245A0 (et)
IS (1) IS2468B (et)
MA (1) MA25087A1 (et)
MY (1) MY136270A (et)
NO (2) NO321952B1 (et)
NZ (2) NZ512818A (et)
OA (1) OA11335A (et)
PA (1) PA8491901A1 (et)
PE (1) PE20001599A1 (et)
PL (1) PL339330A1 (et)
PT (1) PT1044969E (et)
RS (1) RS49836B (et)
SG (2) SG121687A1 (et)
SK (1) SK287339B6 (et)
SV (1) SV2002000047A (et)
TN (1) TNSN00064A1 (et)
TR (1) TR200000837A2 (et)
TW (1) TW553939B (et)
UA (2) UA70928C2 (et)
UY (1) UY26086A1 (et)
YU (1) YU13200A (et)
ZA (1) ZA200001586B (et)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
DE60126997T2 (de) 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
RU2378268C2 (ru) 2003-09-16 2010-01-10 Астразенека Аб Производные хиназолина в качестве ингибиторов тирозинкиназы
EP2392564B1 (en) 2003-09-26 2013-10-23 Exelixis, Inc. c-Met modulators and methods of use
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR100885835B1 (ko) * 2004-05-06 2009-02-26 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
AU2006217692A1 (en) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
WO2008001956A1 (fr) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
EP2170844B1 (en) * 2007-02-21 2016-05-04 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
EP2139868B1 (en) 2007-04-04 2015-07-29 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
US8389531B2 (en) 2007-07-11 2013-03-05 Hetero Drugs Limited Process for erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
TW200925152A (en) * 2007-08-23 2009-06-16 Plus Chemicals S A Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
KR20240011244A (ko) 2009-01-16 2024-01-25 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012028861A1 (en) 2010-07-23 2012-03-08 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20170122809A (ko) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
WO1999055683A1 (en) 1998-04-29 1999-11-04 Pfizer Products Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
ES2278578T3 (es) 2007-08-16
EP1044969B1 (en) 2006-12-13
CN1276370A (zh) 2000-12-13
JP2003176274A (ja) 2003-06-24
GEP20022653B (en) 2002-03-25
HUP0001353A3 (en) 2002-01-28
ID25427A (id) 2000-10-05
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
CA2302965C (en) 2004-02-17
KR20020084903A (ko) 2002-11-13
GT200000037A (es) 2001-09-21
CA2427221A1 (en) 2000-09-30
AP1655A (en) 2006-09-01
KR100430210B1 (ko) 2004-05-03
PT1044969E (pt) 2007-05-31
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
EA005892B1 (ru) 2005-06-30
SG115536A1 (en) 2005-10-28
JP3420549B2 (ja) 2003-06-23
UA70928C2 (uk) 2004-11-15
HU0001353D0 (en) 2000-06-28
OA11335A (en) 2003-12-10
AU781402B2 (en) 2005-05-19
AU2005201494B2 (en) 2008-02-07
HK1029790A1 (en) 2001-04-12
SK4442000A3 (en) 2000-10-09
NO20054715L (no) 2000-10-02
TR200000837A2 (tr) 2000-11-21
CN1215061C (zh) 2005-08-17
CR6165A (es) 2008-10-10
CA2427221C (en) 2008-09-16
EA200000274A3 (ru) 2003-02-27
DE60032275T2 (de) 2007-07-12
SG121687A1 (en) 2006-05-26
UA80955C2 (en) 2007-11-26
BG65194B1 (bg) 2007-06-29
IS5411A (is) 2000-10-02
AR018705A1 (es) 2001-11-28
NZ512818A (en) 2003-01-31
BG104278A (en) 2001-08-31
UY26086A1 (es) 2000-10-31
RS49836B (sr) 2008-08-07
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
DZ3030A1 (fr) 2004-03-27
DK1044969T3 (da) 2007-04-23
NO20001648L (no) 2000-10-02
ATE348098T1 (de) 2007-01-15
EA200201245A1 (ru) 2003-04-24
EA004654B1 (ru) 2004-06-24
KR100430209B1 (ko) 2004-05-03
MA25087A1 (fr) 2000-10-01
CN1699350A (zh) 2005-11-23
CO5160273A1 (es) 2002-05-30
AP1265A (en) 2004-03-26
PA8491901A1 (es) 2001-12-14
US6476040B1 (en) 2002-11-05
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
BRPI0001486B1 (pt) 2019-01-29
SV2002000047A (es) 2002-01-23
NO321952B1 (no) 2006-07-24
DE60032275D1 (de) 2007-01-25
MY136270A (en) 2008-09-30
EA200000274A2 (ru) 2000-10-30
IS2468B (is) 2008-12-15
EA005561B1 (ru) 2005-04-28
JP4074509B2 (ja) 2008-04-09
HRP20000182A2 (en) 2001-04-30
BR0001486A (pt) 2001-05-02
CA2302965A1 (en) 2000-09-30
NZ503683A (en) 2001-09-28
YU13200A (sh) 2002-10-18
PL339330A1 (en) 2000-10-09
IL135245A0 (en) 2001-05-20
AU2005201494A1 (en) 2005-05-05
BRPI0001486B8 (pt) 2021-05-25
EE200000255A (et) 2000-12-15
HUP0001353A2 (hu) 2001-05-28
HU227698B1 (en) 2011-12-28
CN100351242C (zh) 2007-11-28
CZ299426B6 (cs) 2008-07-23
KR20010014658A (ko) 2001-02-26
SK287339B6 (sk) 2010-07-07
EA200201244A1 (ru) 2003-04-24
CZ20001155A3 (cs) 2001-03-14
NO20001648D0 (no) 2000-03-30
PE20001599A1 (es) 2001-01-18
EP1044969A3 (en) 2000-11-29
ZA200001586B (en) 2001-10-01
JP2000290262A (ja) 2000-10-17
TW553939B (en) 2003-09-21

Similar Documents

Publication Publication Date Title
EE04589B1 (et) Vähivastaste ühendite valmistamise protsessid ja vaheühendid
FI20000564A (fi) Menetelmä nanolaminaattien valmistamiseksi
FI20010154A (fi) Menetelmä citalopramin valmistamiseksi
NO20015017L (no) Fremgangsmate for fremstilling av citalopram
NO20010319D0 (no) Fremgangsmåte for fremstilling av Citalopram
PT1210113E (pt) Composicoes de vacinas de combinacao
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
EE04747B1 (et) Amiini-plaatina komplekside valmistamismeetod
FI20011622A (fi) Menetelmä sitalopraamin valmistamiseksi
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20003454L (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
PT1175417E (pt) Compostos substituidos de benzolactamas
ITMI992048A0 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabi cicloalcani
DK1177165T3 (da) Fremgangsmåde til fremstilling af pesticidmellemprodukter
NO20022956L (no) Fremgangsmate for fremstilling av nitroguanidin
NO20000805L (no) FremgangsmÕte for fremstilling av organiske azider
EE200100333A (et) Meetod 2-halo-3-nitro-4-aminopüridiini valmistamiseks ja selleks vajalike vaheühendite saamine
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
NO982975L (no) FremgangsmÕte for fremstilling av fosfatbundne keramer
NO20002558D0 (no) FremgangsmÕte for fremstilling av findisperse eksplosivstoffer

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110330